PsyFi

In this episode of PsyFi, we sit down with Dr Stuart Seidman, a clinical psychologist treating patients on the severe end of mental health disorders. He believes psychedelic medicines are a game-changer for the field of psychology. PsyFi - Unraveling the Mysteries of Psychedelic Science WATCH the live recording: https://youtu.be/nataU-PaWuI Stuart Seidman | Partner, Negev Capital Stuart Seidman has a medical practice in psychopharmacology in New York City, owns an outpatient psychiatry clinic on the Upper West Side, and teaches psychiatry at the Chaim Sheba Medical Center in Israel. He went to medical school at Emory University, did a medical internship at the University of Pennsylvania, and was trained in epidemiology for 2 years at the Centers for Disease Control. He then completed a residency in psychiatry and a fellowship in psychopharmacology at Columbia University. He remained at Columbia as an attending physician for 15 years, during which his research focus was on the role of androgens in CNS function. He has been principal investigator of numerous clinical trials concerning exogenous testosterone and mood. Negev Capital Negev Capital is a psychedelic medical intervention investment fund with assets of USD$20+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP. We believe that psychedelic medications will be not only disruptive to the practice of psychiatry, but hold the potential to reduce enormous amounts of human suffering, and we are committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.

Robin Arnott, CEO of Andromeda Entertainment, talks about life experiences that ultimately led him to creating a unique immersive gaming-and-music art-meets-science offering in the psychedelic space. Robin Arnott, CEO, Andromeda Entertainment, is a game designer and longstanding public speaker in the industry of consciousness technology. He was featured in Netflix’s Screenland and the documentary Game Loading: Rise of the Indies. As the lead developer of SoundSelf: A Technodelic, Robin is an expert in the means by which technology can profoundly impact player consciousness. Video on Youtube: https://youtu.be/EecpyiNF4FY Subscribe today!

PSY FI UNRAVELING THE MYSTERIES OF PSYCHEDELIC SCIENCE We take an evidence-based exploration into the world of psychedelic medicine with leading researchers, clinicians and industry experts. DR. STEVEN MANDEL Founder & President, Ketamine Clinics Los Angeles Dr. Steven Mandel is an internationally-recognized expert & pioneer in the use of ketamine infusion therapy to treat mental health disorders & chronic pain. Dr. Mandel has more than 40 years of experience utilizing ketamine as a board-certified anesthesiologist. He also earned his master’s degree in psychology. He is the founder & president of Ketamine Clinics Los Angeles, a leading ketamine infusion therapy clinic in Southern California. Dr. Mandel is also founder and first president of ASKP. SAM MANDEL Cofounder & Chief Operating Officer, Ketamine Clinics Los Angeles Sam Mandel is a lifelong mental health advocate & entrepreneur. Mandel started Ketamine Clinics Los Angeles with his father, Dr. Steven Mandel, in 2014 and has grown the clinic to be one of the most successful and well-respected ketamine infusion therapy clinics in the US. Mandel is responsible for the day-to-day operations of KCLA and manages its staff of 10. He oversees all non-clinical functions, including patient satisfaction, vendors, marketing, technology, development, & finance. LINKS: https://ketamineclinics.com/ [https://ketamineclinics.com/] TIMESTAMPS: 1:18: Ketamine is not new — supported War Vets in the 70s. 6:35 Among the first Physicians to apply Ketamine with patients. 6:53 In 2014 Many people considered it very experimental. 8:04 3 Different populations of patients. 9:10 Mental health benefits of Ketamine at anesthetic doses. 12:14 Spearheading the movement of using chemicals to promote better mental health. 15:10 Why is Ketamine so effective, so quickly? 17:05 Ketamine works on chemical level and experiential level. 23:50 Evidence-based approach. 28:42 Ketamine vs. Traditional treatment efficacy. 32:30 Ketamine is no longer a last resort. 34:49 Ketamine has no long-term side effects. Quality of Relief. 39:23 Ketamine is an activator rather than a depressant. 42:52 Working with my son. 45:05 Working with my father. 50:37 What about the 17% who don't experience benefits? 55:15 Is Ketamine frequently abused or addictive? 59:44 The largest cause of disability globally? Depression. 1:03:45 Ketamine is the fastest acting, safest, most effective anti-depressant. 1:04:34 Ketamine saves lives.

Video on Youtube: https://youtu.be/XF4Zps6dOVA NOAH CRAFT COFOUNDER & CO-CEO, PEOPLE SCIENCE https://peoplescience.health/ [https://peoplescience.health/] Noah is a physician-scientist-entrepreneur. He is the Co-Founder/Co-CEO of People Science, focused on self-inquiry and the R&D of alternative medicines. He was previously the co-founder/CEO of Science 37, one the industry leaders in Virtual Clinical Trials. Before that, he ran a successful translational research laboratory at LA Biomed and serves as a strategic advisor to multiple biotech companies including Bexson Biomedical. He lives with his wife, son, and 2 dogs in Venice Beach, California. BELINDA TAN CO-FOUNDER & CO-CEO, PEOPLE SCIENCE https://peoplescience.health/ [https://peoplescience.health/] Belinda Tan MD, PhD, is a physician-scientist-entrepreneur who spent her formative professional training years in Los Angeles where she currently resides. Early in her career, she began applying high impact technology ideas to clinical practice with the purpose of providing broader access to quality care. She is Co-Founder and Co-CEO of People Science, a clinical research marketplace for the R&D of alternative medicines. Dr. Tan is in the early founding team and continuing advisor to DirectDerm, the national leader delivering teledermatology services and improving health outcomes among underserved populations. She previously co-founded and served as Chief Medical Officer of Science 37, a venture-backed pioneering market leader in virtual clinical trials that led several groundbreaking first-ever FDA-regulated studies. The company’s focus on bringing clinical research to people in their homes significantly improved diversity among clinical study participants, from an average of 5% to 40%. Dr. Tan is a continuing student of life, a listener, and a mentor. As a wife, mother, daughter, and sister, her first-generation American journey has enriched her appreciation of belonging to a global citizenship and of cultural competence as a healthcare provider and entrepreneur. Her personal and professional pursuits are guided by promoting inclusivity, attribution, and access. Inspired by the needs of people seeking healthcare within the LA County public health system where she trained, Dr. Tan continues to mentor medical students and residents as Assistant Clinical Professor of Medicine at Harbor-UCLA Medical Center. Her board and advisory roles involve the Los Angeles Mayor’s WiSTEM (Women in STEM) Initiative, 826LA, Bexson Biomedical, Seed Health, and VisualDx. She earned her MD and PhD from UCLA and BS from MIT, with additional clinical training at the Memorial Sloan-Kettering Cancer Center and Cornell-New York Presbyterian Hospital. She lives with her husband, son, and two Labradors in Venice Beach.

REID ROBISON, MD, MBA NOVAMIND VENTURES CHIEF MEDICAL OFFICER AND DIRECTOR Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center. He is currently the coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato™. To date, Dr. Robison has guided thousands of ketamine therapy journeys and hundreds of Spravato™ dosing sessions. As a social entrepreneur, Dr. Robison has built a number of purpose-driven companies including Tute Genomics which was acquired by PierianDx in 2016. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and is the founder of the Polizzi Free Clinic, a free mental health clinic for marginalized people based in Salt Lake City, Utah.